ATA176991A - Neue pregna-1,4-dien-3,20-dion-16,17-acetal-21- ester, verfahren zu deren herstellung und diese ester enthaltende arzneimittel - Google Patents

Neue pregna-1,4-dien-3,20-dion-16,17-acetal-21- ester, verfahren zu deren herstellung und diese ester enthaltende arzneimittel

Info

Publication number
ATA176991A
ATA176991A AT0176991A AT176991A ATA176991A AT A176991 A ATA176991 A AT A176991A AT 0176991 A AT0176991 A AT 0176991A AT 176991 A AT176991 A AT 176991A AT A176991 A ATA176991 A AT A176991A
Authority
AT
Austria
Prior art keywords
esters
pregna
dion
dien
acetal
Prior art date
Application number
AT0176991A
Other languages
English (en)
Other versions
AT402930B (de
Inventor
Jose Calatayud
Jose Ramon Conde
Manuel Luna
Original Assignee
Elmuquimica Farm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elmuquimica Farm Sl filed Critical Elmuquimica Farm Sl
Publication of ATA176991A publication Critical patent/ATA176991A/de
Application granted granted Critical
Publication of AT402930B publication Critical patent/AT402930B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT0176991A 1990-09-07 1991-09-06 Neue pregna-1,4-dien-3,20-dion-16,17-acetal-21- ester, verfahren zu deren herstellung und diese esteenthaltende arzneimittel AT402930B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (2)

Publication Number Publication Date
ATA176991A true ATA176991A (de) 1997-02-15
AT402930B AT402930B (de) 1997-09-25

Family

ID=24314964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0176991A AT402930B (de) 1990-09-07 1991-09-06 Neue pregna-1,4-dien-3,20-dion-16,17-acetal-21- ester, verfahren zu deren herstellung und diese esteenthaltende arzneimittel

Country Status (18)

Country Link
US (1) US5482934A (de)
JP (1) JP3292928B2 (de)
KR (1) KR100193085B1 (de)
AT (1) AT402930B (de)
AU (1) AU649472B2 (de)
BE (1) BE1005876A5 (de)
BR (1) BR1100860A (de)
CA (1) CA2050812C (de)
CH (1) CH683343A5 (de)
DE (2) DE4129535C2 (de)
ES (1) ES2034893B1 (de)
FR (1) FR2666585B1 (de)
GB (1) GB2247680B (de)
GR (1) GR1001529B (de)
IT (1) IT1251376B (de)
LU (2) LU88001A1 (de)
NL (2) NL194917C (de)
PT (1) PT98897B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
YU48707B (sh) 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
ATE172739T1 (de) * 1993-04-02 1998-11-15 Byk Gulden Lomberg Chem Fab Neue prednisolonderivate
DK0749438T3 (da) * 1994-03-09 2001-04-02 Byk Gulden Lomberg Chem Fab Hidtil ukendte silylforbindelser og deres anvendelse
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
EA006231B1 (ru) * 2000-11-10 2005-10-27 Алтана Фарма Аг Способ получения 16,17-[(циклогексилметилен)бис(окси)]-11,21-дигидроксипрегна-1,4-диен-3,20-диона или его 21-изобутирата транскетализацией
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PL373433A1 (en) * 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
PT1572217E (pt) 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (de) 2003-06-13 2006-03-22 ALTANA Pharma AG Kombination aus formoterol und ciclesonid
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
CA2538202C (en) * 2003-09-15 2013-01-15 Altana Pharma Ag Use of ciclesonide for the treatment of inflammatory bowel diseases
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
EP1796679A1 (de) * 2004-09-10 2007-06-20 Altana Pharma AG Ciclesonid- und syk-hemmerverbindung und verfahren zu ihrer verwendung
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
RU2008100237A (ru) * 2005-06-14 2009-07-20 Джилид Сайэнс, Инк. (US) ОБЩИЕ ПРОЛЕКАРСТВЕННЫЕ ФОРМЫ СТЕРОИДОВ И β-АГОНИСТОВ (ВАРИАНТЫ), ВКЛЮЧАЮЩИЙ ИХ АЭРОЗОЛЬНЫЙ СОСТАВ (ВАРИАНТЫ) И СПОСОБ ПРЕДОТВРАЩЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ЛЕГОЧНЫХ ВОСПАЛЕНИЙ И/ИЛИ БРОНХОСТЕНОЗА С ИХ ПОМОЩЬЮ
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备泼尼松龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
CN101300265A (zh) * 2005-09-02 2008-11-05 尼科克斯公司 糖皮质激素硝酰氧基衍生物
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US20070135398A1 (en) * 2005-11-02 2007-06-14 Pierluigi Rossetto Process for the preparation of ciclesonide
EP1904514A2 (de) * 2006-02-08 2008-04-02 Sicor, Inc. Kristalline formen von ciclesonide
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (en) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Process for preparing ciclesonide
TW200821316A (en) 2006-07-19 2008-05-16 Astrazeneca Ab Novel compounds 243
BRPI0715231A2 (pt) 2006-08-22 2013-06-25 Ranbaxy Lab Ltd compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto
WO2008062450A2 (en) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Crystalline polymorphs of ciclesonide
CA2663737A1 (en) 2006-09-19 2008-03-27 Cipla Limited Processes for the preparation of ciclesonide and its crystal form
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008075005A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
PT2124944E (pt) * 2007-03-14 2012-05-17 Ranbaxy Lab Ltd Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
EP2022796A1 (de) * 2007-08-07 2009-02-11 Nycomed GmbH Amorphes Ciclesonid
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (de) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. 4-(2-Amino-1-hydroxyethyl)Phenol-Derivate als Agonisten des b2-adrenergen Rezeptors
EP2262823B1 (de) * 2008-03-13 2013-01-23 Farmabios S.p.A. Verfahren zur herstellung von pregnanderivaten
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
CN102908624A (zh) * 2008-05-13 2013-02-06 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
CN102105448B (zh) 2008-05-27 2013-11-13 阿斯利康(瑞典)有限公司 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2407476B1 (de) * 2009-03-09 2014-05-07 Mikasa Seiyaku Co,. Ltd. Steroidverbindung
EP2228368A1 (de) 2009-03-12 2010-09-15 Almirall, S.A. Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
EP2482822B1 (de) 2009-10-01 2018-08-01 Adare Pharmaceuticals, Inc. Oral verabreichte corticosteroid-zusammensetzungen
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
WO2011093814A2 (en) 2010-01-29 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising formoterol and ciclesonide
WO2011136752A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
EP2744479A1 (de) 2011-08-18 2014-06-25 Takeda GmbH Pharmazeutisches aerosolprodukt zur verabreichung mittels oraler oder nasaler inhalation
EP2578570A1 (de) 2011-10-07 2013-04-10 Almirall, S.A. Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
WO2013109212A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (de) 2012-03-20 2013-09-25 Almirall, S.A. Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2016120891A1 (en) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
KR20250069711A (ko) * 2022-07-21 2025-05-19 파이어플라이 바이오, 인크. 글루코코르티코이드 수용체 작용제 및 이의 접합체
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378109B (de) * 1972-05-19 1975-08-18 Bofors Ab
SE378110B (de) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Also Published As

Publication number Publication date
GB2247680A (en) 1992-03-11
US5482934A (en) 1996-01-09
AU8368691A (en) 1992-03-12
JPH04257599A (ja) 1992-09-11
KR100193085B1 (ko) 1999-06-15
FR2666585A1 (fr) 1992-03-13
DE4129535C2 (de) 2001-03-15
IT1251376B (it) 1995-05-09
CA2050812A1 (en) 1992-03-08
ITMI912296A0 (it) 1991-08-28
DE122005000030I2 (de) 2007-12-06
CH683343A5 (de) 1994-02-28
FR2666585B1 (fr) 1994-09-09
JP3292928B2 (ja) 2002-06-17
CA2050812C (en) 2003-07-29
ES2034893A1 (es) 1993-04-01
GR1001529B (el) 1994-03-31
DE4129535A1 (de) 1992-03-12
AU649472B2 (en) 1994-05-26
BR1100860A (pt) 1999-08-31
ITMI912296A1 (it) 1993-02-28
DE122005000030I1 (de) 2005-10-06
PT98897A (pt) 1992-07-31
HK1005881A1 (en) 1999-01-29
NL9101472A (nl) 1992-04-01
LU88001A1 (fr) 1992-06-01
NL194917C (nl) 2003-09-01
GR910100353A (en) 1992-09-11
BE1005876A5 (nl) 1994-02-22
PT98897B (pt) 2000-10-31
GB2247680B (en) 1994-06-01
GB9118967D0 (en) 1991-10-23
NL300196I2 (nl) 2005-10-03
NL300196I1 (nl) 2005-08-01
ES2034893B1 (es) 1994-01-01
KR920006365A (ko) 1992-04-27
LU91205I2 (fr) 2006-05-30
AT402930B (de) 1997-09-25

Similar Documents

Publication Publication Date Title
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE150033T1 (de) N,o-sulfatierte heparosane; verfahren zu deren herstellung und diese enthaltende arzneimittel
DE122005000030I1 (de) Pregna-1, 4-dien-3, 20-dion-16-17-acetal-21-ester,Verfahren zur Herstellung, sowie diese enthaltendepharmazeutische Pr{parate.
DE69632324D1 (de) Pna-dna-chimäre und pna-synthone zu deren herstellung
PT80476A (de) Neue aminotetralinderivate diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3381680D1 (de) 1,4-dihydropyridincarbonsaeure-ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3582447D1 (de) Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte.
DE69314950D1 (de) Okulaerdarreichungsform und verfahren zu ihrer herstellung
DE59610963D1 (de) Neue phenylamidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69205804D1 (de) Vulkanisierbare Fluorkautschukzusammensetzung und Verfahren zu ihrer Herstellung.
DE3777122D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE211745T1 (de) 10,13,15-trioxatricyclo(9.2.1.1. 9.6)- pentadecanon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3483515D1 (de) Zuckerdragiertes arzneimittel und verfahren zu dessen herstellung.
EP0566149A3 (de) Verbundmaterial und Verfahren zu dessen Herstellung.
ATA260590A (de) Glyzerinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3767894D1 (de) 1,2-dithiol-3-thion-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
DE69630873D1 (de) Propylen-1-penten copolymerisate, verfahren zu deren herstellung und zusammensetzungen diese enthaltend
ATA86690A (de) 2-substituierte n,n'-ditrimethoxybenzoylpiperazine, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE69002289D1 (de) Strangpressduese und verfahren zu deren herstellung.
DE59003716D1 (de) Neue diphosphonsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.
DE69515341D1 (de) Diarylethylen-metallogenderivate, verfahren zu deren herstellung und diese enthaltende arzneizusammensetzungen
EP0069154A4 (de) Neue thiazolverbindungen, verfahren zu deren herstellung und diese enthaltendes arzneimittel.
ATE136299T1 (de) Verfahren zur herstellung der racemischen und optisch aktiven 1,2,3,4-tetrahydroisochinolin-3- carbonsäure sowie deren vorprodukte
DE69521142D1 (de) 6-methoxy-1h-benzotriazol-5-carboxamid-derivate, verfahren zur herstellung und diese enthaltende arzneimittel
DE69118340D1 (de) Neue 15-nitro-2-beta, 3 Beta-dihydro und 15-Nitro-2-beta, 3-Beta,6,7-Tetrahydrotabersoninederivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
EFA Change in the company name
EIH Change in the person of patent owner
SZA Application filed for a certificate of protection

Free format text: SZ 34/2008, 20080908

Spc suppl protection certif: SZ 34/2008

Filing date: 20080908

EECC Corrections of claims as to par. 4/2 appealed

Free format text: BERICHTIGUNG FUER ANSPRUECHE 4, 5 UND 6

EZF Grant of a certificate of protection

Free format text: SZ 34/2008, 20080908, EXPIRES:20160906

Spc suppl protection certif: SZ 34/2008

Filing date: 20080908

Expiry date: 20160906

MK07 Expiry

Effective date: 20110906

SPCT Change of the owner of an spc

Owner name: TAKEDA GMBH, DE

Free format text: PRODUCT NAME: CICLESONID; NAT. REGISTRATION NO/DATE: 1-27506, 1-27507, 1-27508 20080403; FIRST REGISTRATION: GB PL 20141/0004 - PL 20141/0006 20040416

Spc suppl protection certif: 34/2008

Filing date: 20080908

Expiry date: 20110906

Extension date: 20160906

Effective date: 20160913

SPCX Expiry of an spc

Free format text: PRODUCT NAME: CICLESONID; NAT. REGISTRATION NO/DATE: 1-27506, 1-27507, 1-27508 20080403; FIRST REGISTRATION: GB PL 20141/0004 - PL 20141/0006 20040416

Spc suppl protection certif: 34/2008

Filing date: 20080908

Expiry date: 20110906

Extension date: 20160906

Effective date: 20160906